

KUVAN® (sapropterin dihydrochloride) Tablets is approved to reduce blood Phe levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). KUVAN is to be used with a Phe-restricted diet.

Important Safety Information

High blood Phe levels are toxic to the brain and can lead to lower intelligence and decrease in the ability to focus, remember and organize information. Any change you make to your diet may impact your blood Phe level. Follow your doctor's instructions carefully. Your doctor and dietitian will continue to monitor and change your diet throughout your treatment with KUVAN.

If you have a fever, or if you are sick, your Phe level may go up. Tell your doctor and dietitian as soon as possible so they can see if they have to adjust your treatment to help keep your blood Phe levels in the desired range.

KUVAN is a prescription medicine and should not be taken by people who are allergic to any of its ingredients. Tell your doctor, if you have ever had liver problems, are nursing or pregnant or may become pregnant, have poor nutrition or are anorexic, your doctor will decide if KUVAN is right for you. Tell your doctor about all the medicines you take.

The most common side effects reported when using KUVAN are headache, diarrhea, abdominal pain, upper respiratory tract infection (like a cold), throat pain, vomiting, and nausea.

To report SUSPECTED ADVERSE REACTIONS, contact BioMarin Pharmaceutical Inc. at **1-866-906-6100**, or FDA at **1-800-FDA-1088** or www.fda.gov/medwatch.

Please read the Patient Package Insert.

KUVAN[®]
(sapropterin dihydrochloride) Tablets

BIOMARIN[®]
Matching Proven Science With Proven Needs

Interested in participating?
Ask your clinic staff how you can enroll.

The Phenylketonuria Demographics, Outcomes, and Safety (PKUDOS) Registry

Teaming up to understand
more about PKU and you

KUVAN[®]
(sapropterin dihydrochloride) Tablets

The PKUDOS Registry

KUVAN was approved by the US Food and Drug Administration (FDA) in December 2007 after multiple studies evaluated its effectiveness and safety in the treatment of phenylketonuria (PKU). BioMarin Pharmaceutical Inc., the maker of KUVAN and a company committed to PKU research and treatment, has created a unique program to collect additional data on the impact of KUVAN on the treatment of PKU. The program includes PKU patients who have tried, are taking, or are about to start treatment with KUVAN, and a subset of that group comprised of pregnant women with PKU.

What is a registry?

A registry is a program used by medical researchers to gather information about patients with a specific disease or who are receiving a specific medication or therapy. It is a voluntary "observational" program. That means you agree to share your test results so researchers can observe your progress to learn more about your condition or the effects of the medication you are taking to treat that condition. No additional tests or changes to your usual treatment plan are needed for you to be part of the registry.

PKUDOS Registry

The purpose of PKUDOS is to collect information from PKU patients so medical researchers can understand more about PKU and the benefits and long-term safety of KUVAN. The registry will evaluate the impact of KUVAN on your blood phenylalanine (Phe) levels, the amount of dietary Phe that you eat, and various other PKU treatment issues. This information will help physicians improve the care of PKU patients.

PKU MOMS Subregistry

There are no studies of KUVAN in pregnant women. If you are pregnant or planning on becoming pregnant, you should talk with your doctor to see if KUVAN is right for you.

Because of the special healthcare concerns during pregnancy, a subregistry has been created to allow researchers to better understand the effects of KUVAN in pregnant women with PKU. The Maternal Phenylketonuria Observational Program (PKU MOMS Subregistry) is designed to collect information on PKU patients during pregnancy and for 1 month after childbirth. Information will also be collected on newborns during their first month of life.

Participating Is Easy

Participating in the PKUDOS Registry

You are eligible to participate if you have taken KUVAN in the past, are currently taking KUVAN, or are about to start KUVAN within the next 90 days, as directed by your healthcare professional.

You may be eligible to participate if you have PKU, your PKU clinic is a participating PKUDOS center, and you provide written authorization that you are willing to participate and share your personal health information. Remember, no one will be able to tell that your information belongs to you except for your healthcare professional. If you are currently participating in a BioMarin-sponsored clinical study of KUVAN, you cannot participate in PKUDOS.

Participating in the PKU MOMS Subregistry

If you enroll in PKUDOS and are pregnant or become pregnant, you may also be eligible to participate in PKU MOMS. To be eligible, you must enroll in the PKU MOMS portion of the registry within 10 weeks of your last menstrual period.

No additional tests will be asked of you during your pregnancy other than what is typically performed on a woman with PKU who is pregnant. After your baby is born, a 1-month follow-up assessment at your PKU clinic will be requested. If you choose to breast-feed and are taking KUVAN, blood samples will be collected from you and from your infant when the infant is 1 month old. A breast milk sample will also be requested from you at that time. Again, all personal information will remain confidential between you and your healthcare professional.

Please see Important Safety Information on back cover.

KUVAN[®]
(sapropterin dihydrochloride) Tablets

What Does It Mean to Participate?

Benefits for you

Your healthcare professional will be able to show you an ongoing record of your care in an easy-to-understand format. This gives your healthcare professional an additional opportunity to keep you informed about your progress over time. Participation is free. There will be no effect on your insurance coverage or the cost of your PKU treatment.

Benefits for future generations

Researchers will be able to access the progress of thousands of patients with PKU who are participating in this registry. The knowledge collected over more than a dozen years will be very informative, allowing the medical community to track the benefits of KUVAN. In this way, you will be contributing to the overall care of PKU patients.

Privacy issues

Each participant will be assigned a unique patient identifier upon enrollment in the registry. Only your healthcare professional will be able to access your information and know it belongs to you. Your results will be collected and viewed in a large database as part of a group.

If you decide to participate, you will be asked to sign an informed consent form. You will be able to ask your healthcare professional any other questions at that time.

Interested in participating?

Ask your clinic staff for more details.